Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript February 22, 2024 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.46, expectations were $-1.47. Intellia Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome […]
Laura Sepp Lorenzino Maury Raycroft Glenn Goddard New England Journal Intellia In Vivo Chief Scientific Officer
Source: yahoo.com